Pharmaceuticals

Oncology Biosimilars Market Expansion Forecast Reaching $9.58 Billion By 2030 At 3.4% CAGR

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Oncology Biosimilars Market In 2026, And How Will Its Value Evolve By 2030?

The oncology biosimilars market has experienced rapid growth in recent years. Its size is projected to expand from $11.35 billion in 2025 to $12.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. The significant growth observed historically is attributable to several factors, including the high cost of reference biologics, the limited availability of oncology biosimilars, increasing cancer prevalence globally, growing hospital and pharmacy infrastructure, and early regulatory approvals for monoclonal antibody biosimilars.

The oncology biosimilars market is anticipated to experience significant expansion in the upcoming years, with its size projected to reach $21.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This forecasted growth is attributable to several factors, including the introduction of new biosimilar drugs like pembrolizumab and pegfilgrastim, the broadening of online pharmacy distribution channels, an increasing embrace of immunomodulators and hematopoietic agents, intensified government initiatives aimed at improving access to cancer care, and a heightened focus on personalized oncology treatment. Throughout the forecast period, prominent trends are expected to include a rise in the adoption of rituximab, trastuzumab, and bevacizumab biosimilars, an expanded utilization of immunomodulators and hematopoietic agents in cancer therapy, growth in g-csf biosimilars for neutropenia management, the expansion of hospital and retail pharmacy channels dedicated to oncology biosimilars, and an overarching emphasis on cost-effective and accessible cancer treatment options.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2821&type=smp

What Key Drivers Are Fueling The Growth Of The Oncology Biosimilars Market?

The production of new oncology biosimilars is primarily driven by the expiration of patents for biologics utilized in cancer treatment. Biologics are protected by patents for a limited duration, and the lapse of these patents enables the creation of novel biosimilars. Biologics are specific drugs synthesized from living organisms that activate the immune system to target cancer cells. Biosimilars, while not identical to biologics, are similar in nature and deliver comparable effectiveness at a reduced cost. For instance, in February 2024, according to the DrugTimes is a Chinese-based company focused on the pharmaceutical and biotech industry, by 2037, more than 25 products will lose patent protection, potentially resulting in a combined revenue decline exceeding $236.4 billion, based on 2024 sales figures. This growing number of patent expirations is projected to significantly increase the demand for developing new oncology biosimilars, thereby boosting the growth of the oncology biosimilars market.

How Is The Oncology Biosimilars Market Broken Down By Segment Categories?

The oncology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars

2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars

3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars

4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

What Emerging Trends Are Seen In The Oncology Biosimilars Market?

Leading companies operating in the oncology biosimilars market are concentrating on developing innovative cancer therapies, including targeted biologics and monoclonal antibodies, to enhance treatment efficacy, patient outcomes, and overall accessibility in oncology care. Monoclonal antibodies (mAbs) are laboratory-engineered proteins designed to recognize and bind specific cancer cell antigens, facilitating precise targeting and immune-mediated destruction. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, merged with Seagen and invested $43 billion to strengthen its oncology portfolio. This strategic move bolsters Pfizer’s presence in cancer therapeutics and accelerates the development of advanced treatments against cancer, a leading cause of death worldwide. The investment also underscores the growing trend of significant capital allocation toward innovative oncology biosimilars to address unmet medical needs and expand global access to cancer care.

Which Players Are Present In The Oncology Biosimilars Market Space?

Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Get The Full Oncology Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Which Region Represents The Largest Share Of The Oncology Biosimilars Market?

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncology Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Oncology Biosimilars Market 2026, By The Business Research Company

Biosimilar Growth Hormone Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795